Oral 5 – High 1-Year Survival Rate of Unresectable Pancreatic Cancer Size Smaller Than 4 cm in Diameter Treated With Concurrent EUS-RFA: An Average Treatment Effect on the Treated Weighted Survival Analysis
Monday, October 24, 2022 | 8:48 AM – 9:00 AM ET | Location: Hall C2
Author Insight from Pradermchai Kongkam, MD, King Chulalongkorn Memorial Hospital
What’s new here and important for clinicians?
Our study is the first single-center retrospective cohort study using propensity score matching comparing survival outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) lesions less than 4 cm who underwent concurrent endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). The propensity score matching was calculated from tumor size, staging, age, age-adjusted Charlson comorbidity index and chemotherapy regimen. We found that the median weighted survival was 14 months in the RFA group versus 6.1 months in the controls (Hazard ratio 0.38, 95%CI 0.17 – 0.84). There may be a greater chance of survival if patients were treated with combined EUS-RFA compared with chemotherapy alone. The data is limited from small sample size and retrospective cohort study design. More large-scale studies should be undertaken in the future. Our team is currently working on a randomized controlled trial to prove the clinical benefits of EUS-RFA in this group of patients.
What do patients need to know?
Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) may significantly improve survival outcomes in patients with unresectable pancreatic ductal adenocarcinoma with primary tumor size less than 4 cm. The data is promising, yet still in experimental stage. Our team and physicians around the world are currently working on the issue to deliver better quality of care to pancreatic cancer patients.
Read the Abstract
Pradermchai Kongkam, MD, King Chulalongkorn Memorial Hospital
kongkam [at] hotmail.com
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.